Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Doxorubicin 5Cyclophosphamide 4anlotinib 3Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Neoadjuvant Therapy 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1spartalizumab 1relmacabtagene autoleucel 1regorafenib 1penpulimab 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × pemigatinib × Sarcoma × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡